British American Tobacco

Exxon Mobil

Pfizer

AT&T

Realty Income

Shielding Your Portfolio with High-Yield Dividend Stocks Amid Market Volatility

辉瑞

Pfizer's 15-Minute Chart Displays Expanding Bollinger Bands and KDJ Golden Cross

Pfizer to Host Conference Call with Analysts on May 5

Pfizer: Guggenheim Reiterates Buy, Raises PT to $36 from $35

Valneva

Pfizer Lyme Vaccine Results: 70% Efficacy, Regulatory Review Ahead

Catalyst<ul> <li>Recent MACD Golden Cross and multiple MACD Death Cross signals indicate bullish momentum for PFE.</li> <li>Most analysts rate PFE Strong Buy or Buy, showing strong institutional optimism despite a conflicting Sell rating.</li> <li>PFE maintains favorable profitability metrics including high ROE and strong interest coverage ratios.</li></ul>Risk<ul> <li>Fund flows show consistent net outflows across all order sizes, indicating investor caution or pessimism.</li> <li>Analyst ratings remain inconsistent, with one major firm maintaining a Sell rating due to valuation concerns.</li> <li>Technical indicators show a volatile and directionally unclear market for PFE, with no strong signals guiding a clear trend.</li></ul>

Key Factors

Pfizer's Lyme disease vaccine candidate showed 73.2% efficacy in the Phase 3 VALOR trial but did not meet its primary endpoint due to fewer cases than expected. Pfizer and Valneva plan to submit the vaccine data to regulatory authorities despite the mixed trial results. Pfizer shares dipped 0.74% on March 23, 2026, amid mixed results from the Lyme vaccine trial and reduced trading volume.

Recent Updates

PFE News